Avalon Ventures XI, L.P. → Janux Therapeutics, Inc. JANX

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 25/100

Passive Schedule 13G filer baseline
Held by 1 tracked 13F institutional manager
Elevated short days-to-cover (6.2 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

1 transaction

0 buys · 0 sales · 1 awards/exercises

Issuer Cluster

2 13D/G filings on this issuer

1 other filing besides this one

Filer Track Record

1 filings by this filer

0 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 6.20

5,327,163 shares short · -6.3% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $13.27M

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-07-08	Campbell David Alan	director, officer	Option exercise	7,000	$4.21	$29K

Other 13D/G Filings on Janux Therapeutics, Inc.

Filed	Form	Filer	Stake	Shares
2025-03-10	SCHEDULE	RA CAPITAL MANAGEMENT, L.P.	19.90%	11,971,377	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →